Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
GNMK > SEC Filings for GNMK > Form 8-K on 12-Mar-2014All Recent SEC Filings

Show all filings for GENMARK DIAGNOSTICS, INC.

Form 8-K for GENMARK DIAGNOSTICS, INC.


12-Mar-2014

Change in Directors or Principal Officers


Item 5.02. Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

The following disclosure is provided pursuant to subsection (e) of Item 5.02 of Form 8-K.

Named Executive Officer 2013 Bonus Payments

On March 6, 2014, the Compensation Committee of the Board of Directors (the
"Compensation Committee") of GenMark Diagnostics, Inc. (the "Company") approved
the following discretionary bonus awards to the Company's President and Chief
Executive Officer, Chief Financial Officer, and each of the Company's other
named executive officers (collectively, the "NEOs"), which were paid in the form
of restricted stock units ("RSUs") based on the closing price of the Company's
common stock on the grant date and which will vest in full on March 1, 2015:
Individual        Cash Equivalent ($) Number of RSUs
Hany Massarany          337,500               27,439
Richard Slansky         105,000                8,537
Jennifer Williams       93,750                 7,622
Michael Gleeson         86,250                 7,012

As previously reported, in March 2013 the Compensation Committee adopted the GenMark Diagnostics, Inc. 2013 Bonus Plan (the "2013 Plan"), which provided for the payment to eligible employees, including the NEOs, of cash incentive compensation for the 2013 calendar year. In March 2014, the Compensation Committee determined that certain financial performance metrics for executive officers under the 2013 Plan were not achieved, which the Compensation Committee largely attributed to the previously reported bankruptcy of Natural Molecular Testing Corporation ("NMTC"), the Company's former largest customer. As a result, the Company's executive officers, including the NEOs, did not receive bonus payouts under the 2013 Plan.

Following a determination that the Company's executive officers would not receive any cash incentive compensation pursuant to the 2013 Plan, the Compensation Committee reevaluated the Company's performance in 2013, considering certain important sales and marketing and research and development milestones and the Company's strong business performance across the organization despite the negative business impact due to the NMTC bankruptcy. Based upon these key accomplishments, and in order to incentivize and retain the Company's executive officers, the Compensation Committee approved discretionary bonus awards to its executive officers, including its NEOs, representing approximately 75% of their respective target bonuses under the 2013 Plan and in the amounts set forth above.

Approval of 2014 Bonus Plan

On March 6, 2014, the Compensation Committee adopted the GenMark Diagnostics, Inc. 2014 Bonus Plan (the "2014 Plan"), which provides for the payment to eligible employees, including the NEOs, of cash incentive compensation for the 2014 calendar year performance period. Consistent with past practice, the Compensation Committee established a target bonus for Mr. Massarany under the 2014 Plan equal to100% of his annual base salary and established a target bonus for each of the other NEOs equal to 50% of their respective 2014 base salaries. Bonuses payable under the 2014 Plan are based on certain financial, commercial and product development goals as approved by the Compensation Committee. Based on actual performance, a participant in the 2014 Plan may receive between 0% and 170% of his or her target bonus amount under the 2014 Plan. The foregoing description of the 2014 Plan is only a summary, does not purport to be complete, and is qualified in its entirety by reference to the full text of the 2014 Plan, a copy of which is filed hereto as Exhibit 99.1. Item 9.01. Financial Statements and Exhibits.

(d) The following exhibit is filed with this Current Report:

Exhibit Number Description
99.1 The GenMark Diagnostics, Inc. 2014 Bonus Plan


  Add GNMK to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for GNMK - All Recent SEC Filings
Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.